- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.
The Food and Drug Administration (FDA) has granted 510(k) clearance for PlaqueIQ™, an emerging software that may enhance quantification of arterial plaque buildup shown on coronary computed tomography angiography (CCTA) imaging.
Employing image restoration algorithms to reduce motion and calcium blooming artifacts, the Plaque IQ software creates 3D modelling of coronary arteries via data segmentation and subsequently provides quantified assessment of tissue composition and structure, according to Elucid, the developer of PlaqueIQ.
Offering an interactive visualization of coronary anatomy and plaque quantification on multiple views, the PlaqueID software recently garnered 510(k) clearance from the Food and Drug Administration (FDA). (Images courtesy of Elucid.)
Emphasizing that approximately half of the United State population between 45 to 84 years of age have atherosclerosis without symptomatic presentations, Elucid maintained that PlaqueIQ may facilitate enhanced visualization and characterization of arterial plaque, and prevention of major adverse cardiovascular events.
“It’s time to shift our focus from merely estimating risk and treating risk of MI to directly visualizing and treating the disease itself by looking at the coronary arteries,” maintained Amir Ahmadi, M.D., an associate professor of medicine and cardiology at the Icahn School of Medicine at Mount Sinai in New York, N.Y. “I believe that PlaqueIQ will enable physicians to better ‘see’ the disease — specifically plaque quantity and type — so that we can treat patients with greater precision and in (a) personalized manner, improve their quality of life, and ultimately prevent (myocardial infarction) and stroke more effectively.”
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.
